van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, Ij RG
The gut microbiome influences GLP-1 production naturally, and maintaining microbial diversity may support the medication mechanisms
GLP-1 RA SmPCs (e.g., semaglutide) generally report no clinically relevant effect on overall drug exposure for most oral medicines, but individual monitoring remains prudent for narrow therapeutic index agents
For example, in 20242025, leading firms such as Kyowa Hakko Bio, KOHJIN Life Sciences, and Lesaffre expanded their portfolios with liposomal, nano-formulated, and plant-based glutathione offerings, enhancing bioavailability, stability, and sustainability
That is the kind of messaging that is both persuasive and medically responsible
10.1016/S0076-6879(05)01024-4 14 AwasthiY